Management of hepatic encephalopathy in children

Postgraduate Medical Journal

Volumn 86, Issue 1011, 2010, Pages 34-41

  Arya, Ravindra ^a   Gulati, Sheffali ^a   Deopujari, Satish ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Gupta Nursing Home   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMMONIA; AMPICILLIN; ANTICONVULSIVE AGENT; ANTIPYRETIC AGENT; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; CARNITINE; DIURETIC AGENT; ELECTROLYTE; FLUMAZENIL; GLUCOSE; LACTULOSE; METRONIDAZOLE; MIDAZOLAM; NITROGEN; ORNITHINE ASPARTATE; OXAZEPAM; PARACETAMOL; PHENYLACETIC ACID; POTASSIUM; PROBIOTIC AGENT; RIFAMYCIN; SEDATIVE AGENT; SODIUM; UNINDEXED DRUG; VANCOMYCIN; VASOPRESSIN; ZINC;

ABSENCE OF SIDE EFFECTS; AGITATION; AIRWAY; AMMONIA BLOOD LEVEL; ANTIBIOTIC THERAPY; ASCITES; ASSISTED VENTILATION; BLOOD CLOTTING DISORDER; BRAIN EDEMA; BREATHING; CHILD CARE; CIRCULATION; CLINICAL TRIAL; COMATOSE PATIENT; COMPARATIVE STUDY; CONFUSION; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG INTOXICATION; DRUG MEGADOSE; ENTEROCOCCUS FAECIUM; EXCHANGE BLOOD TRANSFUSION; FLUID BALANCE; FLUID RESUSCITATION; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEMODIALYSIS; HEMOPERFUSION; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERALDOSTERONISM; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; INTENSIVE CARE; INTRACRANIAL PRESSURE; INTRAVENOUS ADMINISTRATION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LACTOBACILLUS ACIDOPHILUS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER METABOLISM; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; NASOGASTRIC TUBE; NAUSEA; NEUROPROTECTION; NITROGEN BALANCE; PLASMAPHERESIS; REVIEW; SALT INTAKE; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

AMMONIA; BRAIN EDEMA; CHILD; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMANS; INFECTION; KIDNEY DISEASES; LIVER TRANSPLANTATION;

EID: 74749097449     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.079467     Document Type: Review

References (76)

1. Suchy FJ. Fulminant hepatic failure. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 17th rev edn. Pennsylvania, USA: Saunders, 2004:1341-3.
2. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997;337:473-9.
3. Chu CJ, Chang CC, Wang TF, et al. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure: role of nitric oxide synthase isoforms. J Gastroenterol Hepatol 2006;21:1194-9.
4. Nazer H, Nazer D. Hepatic encephalopathy. http://www.emedicine.com (accessed 15 Sep 2008).
5. Whitington PF, Soriano HE, Alonso EM. Fulminant hepatic failure in children. In: Suchy FJ, Sokol RJ, Balistreri WF, eds. Liver disease in children. 2nd rev edn. New York, USA: LWW, 2001; 63-94.
6. Arya R, Chansoria M. Management of pediatric hepatic encephalopathy. Paediatrics Today 2004;VII:284-1.
7. Conn HO, Lieberthal MM. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins, 1979.
8. Kalra V, Murali JV. Fulminant hepatic failure and hepatic encephalopathy. In: Sachdev HPS, Puri RK, Bagga A, et al, eds. Principles of pediatric and neonatal emergencies. N Delhi: Jaypee Brothers, 1994:172-81.
9. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987;7:639-43.
10. Festi D, Vestito A, Mazzella G, et al. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006;73:94-101.
11. Ito S, Miyaji H, Azuma T, et al. Hyperammonaemia and Helicobacter pylori. Lancet 1995;346:124-5.
12. Wiedmann B, Kircheis G, Klauk S, et al. The influence of Helicobacter pylori (Hp) on protein-induced hyperammonemia (0.5 g/kg B.W.) in cirrhotic patients without hepatic encephalopathy. Hepatology 1996;24:453A.
13. Passi GR. Hepatic encephalopathy. In: Gupte S, ed. Recent advances in pediatrics special volume 9- Neurology. New Delhi: Jaypee Brothers, 2001:30-42.
14. Riyaz A. Pediatric gastroenterology and hepatology. 2nd rev edn. Hyderabad, India: Paras Publishing, 2003. p. 311-14.
15. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993;233:385-92.
16. Camma C, Fiorello F, Tine F, et al. Lactitol in treatment of chronic hepatic encephalopathy: a meta analysis. Dig Dis Sci 1993;38:916-22.
17. Blanc P, Daures JP, Rouillon JM, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta analysis. Hepatology 1992;15:222-8.
18. Gammal SH, Jones EA. Hepatic encephalopathy. Med Clin North Am 1989;73:793.
19. Uribe M, Marquez MA, Garcia-Ramos G, et al. Treatment of chronic portal-systemic encephalopathy with lactose in lactase deficient patients. Dig Dis Sci 1980;25:924-8.
20. Weber FL Jr, Fresard KM, Lally BR. Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982;82:213-17.
21. Weber FL Jr. Combination therapy with lactulose or lactitol and antibiotics. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington (IL): Medi-Ed Press, 1994:285-97.
22. Macbeth WAAG, Kass EH, McDermott WV Jr. Treatment of hepatic encephalopathy by alteration of intestinal flora and Lactobacillus acidophilus. Lancet 1965;1:399-403.
23. Read AE, McCarthy CF, Heaton KW, et al. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy. Br Med J 1966;1:1267-9.
24. Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;23:39-46.
25. Lata J, Jurankova J, Pribramska V, et al. Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis. Vnitr Lek 2006;52:215-9.
26. Kircheis G, Quack G, Erbler H. L-ornithine-L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington (IL): Medi-Ed Press, 1994:373-83.
27. Liehr H, Huth M, Kircheis G, et al. A comparison of L-ornithine-L-aspartate and lactulose in the management of chronic liver disease and hepatic encephalopathy (HE). J Gastroenterol Hepatol 1992;7:A106.
28. Chainuvati T, Plengvanit U, Viranuvatti V. Ornicetil on encephalopathy: effect of ornicetil (ornithine alpha-ketoglutarate) on encephalopathy in patients with acute and chronic liver disease. Acta Hepatogastroenterol 1977;24:434-9.
29. Herlong HF, Maddrey WC, Walser M. The use of ornithine salts of branched-chain ketoacids in portal-systemic encephalopathy. Ann Intern Med 1980;93:545-50.
30. Bruha R, Drastich P, Hulek P, et al. The diagnostics and therapy of hepatic encephalopathy. Recommendations of of the working group on portal hypertension in the Czech Hepatology Society and the J.E. Purkinje Czech Medical Society. Vnitr Lek 2006;52:85-6.
31. Mendenhall CL, Rouster S, Marshall L, et al. A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986;81:540-3.
32. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a doubleblind randomized trial. Hepatology 1992;16:138-44.
33. DiCarlo JV, Frankel LR. Neurologic stabilization. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson textbook of pediatrics. 17th rev edn. Pennsylvania, USA: Saunders, 2004.
34. Sussmann NL. Fulminant hepatic failure. In: Zakim D, Boyer TD (eds). Hepatology. A textbook of liver diseases. 3rd rev edn. Philadelphia: WB Saunders, 1996:1.
35. Gregory PB, Knauer CM, Kempson RL, et al. Steroid therapy in severe viral hepatitis. N Engl J Med 1976;294:681-9.
36. Raghavan M, Marik PE. Therapy of intracranial hypertension in patients with fulminant hepatic failure. Neurocrit Care 2006;4:179-89.
37. Wendon JA, Harrison PM, Keays R, et al. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994;19:1407-13.
38. Leite MC, Brolese G, de Almeida LM, et al. Ammonia-induced alteration in S100B secretion in astrocytes is not reverted by creatine addition. Brain Res Bull 2006;70:179-85.
39. Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure: potential for pediatric patients. Paediatr Drugs 2006;8:1-13.
40. Friedman LS. Liver, biliary tract & pancreas. In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current medical diagnosis and treatment. 38th rev edn. Norwalk, Connecticut, USA: Appleton & Lange, 1999:638-78.
41. Trevor AJ, Way WL. Sedative-hypnotic drugs. In: Katzung BG, ed. Basic and clinical pharmacology. 6th rev edn. Norwalk, Connecticut, USA: Appleton and Lange, 1995.
42. Scollo - Lavizarri G, Steinmann E. Reversal of hepatic coma by benzodiazepine (BDZ) antagonist. Lancet 1985;325:1.
43. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971;2:75-80.
44. Charlton MR. Branched chains revisited. Gastroenterology 1996;111:252-5.
45. Schafer DF, Jones AE. Hepatic encephalopathy. In: Zakim D, Boyer TD, eds. Hepatology. A textbook of liver diseases. 2nd rev edn. Philadelphia: WB Saunders, 1990:447-60.
46. Fabbri A, et al. Overview of randomized controlled trials of oral branched chain amino acids treatment in chronic hepatic encephalopathy. JPEN J Parentr Enteral Nutr 1996;20:159-64.
47. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994;19:518-33.
48. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006;136:295S-8S.
49. Siciliano M, Annicchiarico BE, Lucchese F, et al. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visual-evoked potentials in cirrhotic patients with hepatic encephalopathy. Clin Exp Pharmacol Physiol 2006;33:76-80.
50. Malaguarnera M, Pistone G, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005;11:7197-202.
51. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Lancet 1984;2:493-5.
52. Marchesini G, Fabbri A, Bianchi G, et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-92.
53. Schölmerich J, Langenberger G, Steiert B, et al. Long term zinc substitution in patients with zinc deficiency in liver cirrhosis - results of a placebo controlled trial. Gastroenterology 1986;90:1765.
54. Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy: results of a double-blind crossover trial. Dig Dis Sci 1991;36:1204-8.
55. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993;2:414-6.
56. Krieger D, Krieger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-4.
57. Cotzias GC. Manganese in health and disease. Physiol Rev 1958;38:503-32.
58. Pujol A, Pujol J, Graus F, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993;43:65-9.
59. Krieger D, Herrmann S, Jansen O, et al. Clinical significance of hyperintense globus pallidus on T1-weighted MRI in patients with liver failure. Neurology 1995;45:A299.
60. Thuluvath PJ, Edwin D, Yue NC, et al. Increased signals seen in globus pallidus in T1-weighted magnetic resonance imaging in cirrhotics are not suggestive of chronic hepatic encephalopathy. Hepatology 1995;21:440-2.
61. Becker CE, Olson KR. Management of the poisoned patient. In: Katzung BG, ed. Basic and clinical pharmacology. 6th rev edn. Norwalk, Connecticut, USA: Appleton and Lange, 1995:909.
62. Gitlin N. Hepatic encephalopathy. In: Zakim D, Boyer TD, eds. Hepatology: a textbook of liver disease. 3rd rev ed. vol. 1. Philadelphia: W.B. Saunders, 1996:605-17.
63. Ferenci P. Hepatic encephalopathy. In: McIntyre N, Benhamou J-P, Bircher J, et al, eds. Oxford textbook of clinical hepatology. vol. 1. Oxford (England): Oxford University Press, 1991:473-83.
64. Lunzer M. Treatment of chronic hepatic encephalopathy with L-dopa. Gut 1974;15:555.
65. Uribe M, Farca MA, Marquez G, et al. Treatment of chronic Porto-systemic encephalopathy with bromocriptine. Gastroenterology 1979;76:1347.
66. Rivera - Penera T, Moreno J, Skaff C, et al. Delayed encephalopathy in fulminant hepatic failure in the pediatric population and the role of liver transplantion. J Pediatr Gastroenterol Nutr 1997;24:128-34.
67. Hattori H, Higuchi Y, Tsuji M, et al. Living related liver transplantation and neurological outcome in children with fulminant hepatic failure. Transplantation 1998;65:686-92.
68. O'Grady J, Alexander G, Hayllar K, et al. "Early indicators of prognosis in fulminant hepatic failure". Gastroenterology 1989;97:439-45.
69. Polson J, Lee W. "AASLD position paper: the management of acute liver failure." Hepatology 2005;41:1179-97.
70. Sheil AG. The new age of liver transplantation. Aust N Z J surg 1996;66:698-706.
71. Tsai MH, Chen YC, Wu CS, et al. Extracorporal liver support with molecular adsorbents recirculating system in patients with hepatitis B-associated fulminant hepatic failure. Int J Clin Pract 2005;59:1289-94.
72. Catalina-Rodriguez MV, Banares-Canizares R. Artificial liver support systems: update on albumin dialysis (MARS). Gastroenterol Hepatol 2005;28:453-60.
73. Williams R. Fulminant hepatic failure. Post grad Med J 1983;59:33-41.
74. Gimson AES, Langley PG, Hughes RD, et al. Prostacycline to prevent platelet activation during charcoal hemoperfusion in fulminant hepatic failure. Lancet 1980;1:173-5.
75. Hughes RD, Ton HY, Langley PG, et al. Albumin coated Amberlite XAD-7 resin for hemoperfusion in acute liver failure (Part II). In vivo evaluation. Artif Organs 1979;3:23-6.
76. Redeker AG, Yamahiro HS. Controlled trial of exchange transfusion therapy in fulminant hepatic failure. Lancet 1973;1:3-6.